Bio Medica Laboratories IPO Listing Details
| Listing Date | May 29th, 2026 |
| NSE Code | BMLL |
| ISIN Code | INE1BKA01015 |
| Offer Price | ₹132 to ₹139 |
| Face Value | ₹10 |
| Listing Price | ₹111.20 |
Details about Bio Medica Laboratories IPO
Bio Medica Laboratories has received approval from SEBI for an IPO of ₹52.43 crores, in which the firm will raise ₹47.19 crores via a fresh issue with a face value of ₹10 each.
Moreover, the company has set up a price band between ₹132 to ₹139 per share.
In this IPO, a total of 2000 shares were available in 2 lot sizes for the minimum Retail category and maximum Retail category.
S-HNI (Min) has a total of 3000 shares in 3 lot sizes. S-HNI (Max) has a total of 7000 shares in 7 lot sizes. B-HNI (Min) has a total of 8000 shares in 8 lot sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum & Maximum investment of ₹2,78,000.
- S-HNI (Minimum): Minimum investment of ₹4,17,000.
- S-HNI (Max): Maximum investment of ₹9,73,000.
- B-HNI (Min): Minimum investment of ₹11,12,000.
Subscription duration of the Bio Medica Laboratories IPO
The opening date of the Bio Medica Laboratories IPO subscription was May 21, 2026, and the closing date was May 25, 2026. The Bio Medica Laboratories IPO allotment was finalised on May 26, 2026, and the IPO listing is on May 29, 2026.
Funds Deployment of This Company
- The funds raised from the fresh issue will be used towards the repayment of the loan.
- Some funds will be used towards the enhancement of its existing production capabilities by setting up a new manufacturing facility at the existing premises.
- Lastly, the remaining will go towards the General Corporate Purpose.
About the Bio Medica Laboratories IPO
Bio Medica Laboratories is India’s growing manufacturer of parenteral medicines (injections). The firm offers a wide range of injectable products in the form of liquid injections and dry powder injections for humans as well as animals. Its product range includes injectables for the domestic market, Injectables for export, and Injectables for veterinary.
Their products are sold in various packaging, including ampoules and vials. The firm has also established a reputation for being a leader in offering reliable yet effective solutions in the healthcare sector. The company also claims to offer high-quality and safe products, followed by Good Manufacturing Practices (GMP and GLP).
Bio Medica Laboratories IPO Company Financial Report
The company reported revenue of ₹38.33 crores in 2025 against ₹15.34 crores in 2024. The company reported a profit of ₹9.79 crores in 2025 against a profit of ₹2.50 crores in 2024.
